At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 160 target
Drug / intervention
Eribulin,cisplatin +1 moredrug
Likely dose
Eribulin,cisplatin 1.4mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Single-center, Randomized Study of Eribulin Plus Cisplatin (EP) Versus Gemcitabine Plus Cisplatin (GP) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Eribulin,cisplatin and Gemcitabine,cisplatin for Breast Cancer. Targeting 160 participants across 1 site.
Detailed Summary
Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
202120222023202420252026
First PostedAug 2020
Enrollment StartOct 2020
Primary CompletionJul 2022
Study CompletionOct 2022
TodayJul 2026
First PostedAug 18, 2020
Enrollment StartOct 8, 2020
Primary CompletionJul 30, 2022
Study CompletionOct 31, 2022
TodayJul 1, 2026
Enrollment to primary: 1.8 yearsPosted 5.9 years ago
Interventions
Eribulin,cisplatindrug
Eribulin 1.4mg/m2, IV , D1, D8；Cisplatin 75 mg/m2, IV，D1
Gemcitabine,cisplatindrug
Gemcitabine 1250 mg/m2, IV , D1, D8； Cisplatin 75 mg/m2, IV, D1